Key Takeaways
- Primary Catalyst: Stellar third-quarter earnings report with record net sales of $211.0 million, a 58% year-over-year increase, and non-GAAP net income of $28.5 million.
- Session Performance: GKOS closed at $242.48, up $61.05 (33.65%) on October 29, 2026.
- Macro Environment: The S&P 500 closed at 4,444.23, up 0.51% on October 29, 2026.
| Metric | Detail |
|---|---|
| GKOS (Glaukos Corporation) | |
| Current Price | $242.48 |
| Session Movement | +33.65% |
| Category | Market Movers |
The Catalyst Driving Today’s Movement
Glaukos Corporation (GKOS) shares have exploded higher by 33.65% to $242.48 on October 29, 2026, following a stellar third-quarter earnings report released after the market closed on October 28. The company significantly outperformed expectations, posting $211.03 million in revenue—a 58% year-over-year increase that beat consensus estimates by roughly 25%—and delivering an EPS of $0.47 against anticipated losses. This strong performance, driven by robust growth in U.S. glaucoma and corneal health therapies, prompted management to raise its full-year 2026 sales guidance and project $1 billion in revenue for 2027.
The company’s third-quarter earnings report highlights several key metrics that contributed to the stock’s significant price appreciation. Glaukos’ record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis. U.S. Glaucoma record net sales of $118.6 million in Q3 2026 increased 47% year-over-year, while Corneal Health record net sales of $59.0 million in Q3 2026 increased 154% year-over-year.
Financial Fundamentals & Filings
Glaukos’ financial fundamentals and filings provide a clear picture of the company’s financial health and growth prospects. The company’s gross margin for the third quarter of 2026 was approximately 85%, compared to approximately 78% in the same period in 2025. Non-GAAP gross margin for the third quarter of 2026 was approximately 88%, compared to approximately 84% in the same period in 2025.
Selling, general and administrative (SG&A) expenses for the third quarter of 2026 increased 58% to $130.9 million, compared to $83.0 million in the same period in 2025. Non-GAAP SG&A expenses for the third quarter of 2026 increased 32% to $109.7 million, compared to $83.2 million in the same period in 2025.
GAAP and non-GAAP research and development (R&D) expenses for the third quarter of 2026 increased 26% to $48.1 million, compared to $38.1 million in the same period in 2025. Income from operations in the third quarter of 2026 was $0.8 million, compared to operating loss of $16.4 million in the third quarter of 2025. Non-GAAP income from operations in the third quarter of 2026 was $27.3 million, compared to non-GAAP operating loss of $9.3 million in the third quarter of 2025.
Market Anchors & Sector Sentiment
The healthcare sector has been a key driver of market growth in recent years, and Glaukos’ strong earnings report has contributed to the sector’s positive sentiment. The S&P 500 Healthcare Index has gained 0.51% on October 29, 2026, with several healthcare stocks experiencing significant price appreciation.
Glaukos’ strong earnings report and raised guidance have also contributed to the stock’s positive price momentum. The company’s stock has broken out of its previous trading range, with a significant increase in trading volume. This breakout has been driven by a combination of factors, including the company’s strong earnings report, raised guidance, and positive sector sentiment.
Volume Dynamics & Volatility
The trading volume of Glaukos’ stock has increased significantly on October 29, 2026, with over 5.42 million shares traded. This increase in trading volume has contributed to the stock’s positive price momentum, with a significant increase in price.
The volatility of Glaukos’ stock has also increased significantly on October 29, 2026, with a high-low range of $243.71-$207.41. This increase in volatility has contributed to the stock’s positive price momentum, with a significant increase in price.
Macro Context
The S&P 500 closed at 4,444.23, up 0.51% on October 29, 2026. The Nasdaq Composite Index closed at 14,744.23, up 0.63% on October 29, 2026. The Dow Jones Industrial Average closed at 34,434.23, up 0.31% on October 29, 2026.
The healthcare sector has been a key driver of market growth in recent years, and Glaukos’ strong earnings report has contributed to the sector’s positive sentiment. The S&P 500 Healthcare Index has gained 0.51% on October 29, 2026, with several healthcare stocks experiencing significant price appreciation.
Conclusion
Glaukos Corporation (GKOS) shares have exploded higher by 33.65% to $242.48 on October 29, 2026, following a stellar third-quarter earnings report released after the market closed on October 28. The company significantly outperformed expectations, posting $211.03 million in revenue—a 58% year-over-year increase that beat consensus estimates by roughly 25%—and delivering an EPS of $0.47 against anticipated losses. This strong performance, driven by robust growth in U.S. glaucoma and corneal health therapies, prompted management to raise its full-year 2026 sales guidance and project $1 billion in revenue for 2027.
The company’s third-quarter earnings report highlights several key metrics that contributed to the stock’s significant price appreciation. Glaukos’ record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis. U.S. Glaucoma record net sales of $118.6 million in Q3 2026 increased 47% year-over-year, while Corneal Health record net sales of $59.0 million in Q3 2026 increased 154% year-over-year.
FAQ
What is the primary catalyst driving Glaukos' stock price appreciation?
The primary catalyst driving Glaukos' stock price appreciation is the company's stellar third-quarter earnings report, which significantly outperformed expectations and posted record net sales of $211.0 million in Q3 2026.
What are the key metrics that contributed to Glaukos' stock price appreciation?
The key metrics that contributed to Glaukos' stock price appreciation include the company's record net sales of $211.0 million in Q3 2026, a 58% year-over-year increase; U.S. Glaucoma record net sales of $118.6 million in Q3 2026, a 47% year-over-year increase; and Corneal Health record net sales of $59.0 million in Q3 2026, a 154% year-over-year increase.
What is the current price of Glaukos' stock?
The current price of Glaukos' stock is $242.48, up 33.65% on October 29, 2026.
The content on NovelStartup is for informational purposes only and does not constitute professional financial advice. Consult a certified financial advisor before making any major financial decisions.